Sociedad Americana de Hirudoterapia

State Company for Marketing Drugs and Medical Appliances — KIMADIA

KIMADIA · Iraq · middle east

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Iraq's KIMADIA (State Company for Marketing Drugs and Medical Appliances) — the principal national entity for procurement, registration and oversight of medicines and medical devices; leech-specific regulatory pathway has not been independently verified by ASH.

Regulatory Profile

Agency type
national regulator
Region
middle east
Country
Iraq
Leech status
unregulated
Last ASH review
2026-05-26

Relevant Regulation Codes

  • Iraqi Drug Control Law (No. 40 of 1970 and its amendments)
  • Iraqi Ministry of Health regulations on medical devices and biomedical products

Prescriber Requirements

  • Iraqi Medical Association–registered physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

KIMADIA and Ministry of Health registration as applicable; Arabic and English-language labelling. Standard cold-chain conditions; post-conflict reconstruction context may introduce logistical constraints.

Import/Export Rules

KIMADIA and Ministry of Health import authorisation; Ministry of Agriculture / veterinary services clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Not covered under public insurance schemes for leech therapy specifically.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general medical device / traditional medicine framework as appropriate. The Kurdistan Region of Iraq operates parallel health structures under the Kurdistan Regional Government; ASH has not independently mapped how this affects live-organism medical device oversight.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.